Article

Allergan introduces new drop for dry eye

Allergan Inc. has introduced an over-the-counter artificial tear (Optive Sensitive Preservative-Free Lubricant Eye Drops) for patients who have dry eye or dryness following LASIK.

Key Points

Irvine, CA-Allergan Inc. has introduced an over-the-counter artificial tear (Optive Sensitive Preservative-Free Lubricant Eye Drops) for patients who have dry eye or dryness following LASIK.

The drop is part of a line of artificial tears with a dual-action formula designed to provide a lubricating, hydrating, protective shield on the surface of the eye and also penetrate below the surface to provide corneal epithelial cells osmoprotection from excessive salt levels.

In a 30-day, randomized, controlled trial of 316 patients with dry eye, 157 patients who received the new artificial tear saw a statistically significant improvement in six common signs and symptoms of dry eye when compared with another drop (Refresh Plus, Allergan), according to the company. In a separate 90-day, randomized, controlled trial of 228 patients who had undergone LASIK, those who used the new drop experienced less ocular surface staining at 2 weeks after surgery when compared with patients who had used the other aforementioned artificial tear, according to the company. This trial also demonstrated a statistically significant improvement from baseline in patients' evaluation of dry eye symptoms, Allergan officials reported.

The new formulation is available in unit-dose vials.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.